

Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025

Biomed Industries, Inc. Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Receptor Agonist for the Treatment of Obesity at ENDO 2025

SAN JOSE, CA, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- [Biomed Industries, Inc.](https://www.biomedindustries.com) (Biomed) today announced that its CEO Dr. Lloyd Tran presented topline results from the Phase 2 clinical trial of NA-931, a novel oral quadruple receptor agonist for obesity, at the for ENDO 2025, July 12-15, 2025, at the Moscone Convention Center, San Francisco.



Biomed Industries, Inc- logo

“

NA-931 showed excellent safety and efficacy in Phase 2 as a first-in-class oral quadruple agonist. We're excited to advance to Phase 3 to offer a more effective, well-tolerated obesity treatment.”

*Dr. Lloyd L. Tran, CEO of
Biomed*

ENDO, the annual meeting of the Endocrine Society, has led advancements in hormone science and public health for more than a century. With over 7,000 global attendees, ENDO remains the premier event for endocrinology research and clinical innovation.

LANDMARK FINDINGS FOR A NOVEL ORAL THERAPY

Dr. Tran's presentation, titled “NA-931, A Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight Without Muscle Loss”, highlighted the drug's compelling clinical profile. NA-931 represents a breakthrough approach by simultaneously targeting four metabolic hormone pathways to achieve weight loss

without compromising muscle mass.

In his remarks, Dr. Tran emphasized the central role endocrinologists play in managing obesity, noting that “imbalances in hormones such as insulin, GLP-1, and thyroid hormones can not only

drive weight gain but are also exacerbated by obesity itself, creating a self-reinforcing cycle.” He underscored how NA-931’s mechanism may help break this cycle through comprehensive metabolic modulation.

PHASE 2 CLINICAL RESULTS

The Phase 2 study was a 13-week, randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and efficacy of NA-931 in 125 adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity.

Body Weight Reduction

- NA-931 demonstrated dose-dependent reductions in body weight, achieving up to 13.8% mean weight loss at the 150 mg daily dose.
- This represents a 12.4% greater weight loss compared to placebo.
- 72% of NA-931-treated participants achieved $\geq 12\%$ weight loss, compared to only 2% in the placebo group.


Safety and Tolerability

- Treatment-emergent adverse events (TEAEs) were generally mild and transient.
- Gastrointestinal (GI) symptoms were the most commonly reported, with 83% classified as insignificant.
- Mild nausea and vomiting were reported in 7.3%, and diarrhea in 6.3% of treated subjects.
- Importantly, no muscle loss was observed.
- There were no clinically meaningful differences in GI-related adverse events between NA-931 and placebo groups.


“The Phase 2 results of NA-931 highlight its potential as a first-in-class oral quadruple receptor agonist for weight loss, with excellent safety and efficacy,” said Dr. Lloyd L. Tran, CEO of Biomed Industries. “We are excited to advance NA-931 to Phase 3 trials and provide a more comprehensive, well-tolerated treatment for obesity.”

ADDRESSING THE GLOBAL OBESITY CRISIS

Obesity is a critical public health crisis affecting over 650 million people worldwide, with projections indicating that more than 50% of the global population could be affected by 2035. It



Biomed pipeline



NA-931 for weight loss

is a key risk factor for type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and chronic kidney disease.

Existing therapies often focus on single mechanisms and may lead to muscle loss or intolerable side effects. NA-931's multi-receptor approach offers a promising new strategy by restoring metabolic balance while maintaining muscle mass and minimizing adverse events.

ABOUT NA-931

NA-931 is a first-in-class, orally active quadruple receptor agonist designed to activate IGF-1, GLP-1, GIP, and glucagon pathways. It delivers clinically significant weight loss and glycemic control, as demonstrated in both Phase 1 and Phase 2 trials—without the typical trade-offs seen in current obesity drugs. (ClinicalTrials.gov ID: NCT06564753)

ABOUT BIOMED INDUSTRIES, INC.

Biomed Industries, Inc. is a clinical-stage biopharmaceutical company developing next-generation therapies for unmet medical needs in metabolic, neurodegenerative, and chronic diseases. Its robust pipeline includes novel treatments for Alzheimer's disease, ALS, Traumatic Brain Injury, Major Depressive Disorder, Diabetes, Obesity, MASH, Stroke, and rare diseases such as Rett Syndrome.

□ Website: www.biomedind.com

For media inquiries and additional information, please contact:

Michael Willis

Biomed Industries, Inc.

+1 800-824-5135

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/831414400>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.